J Biol Chem, Vol. 274, Issue 42, 30266-30272, October 15, 1999
CIS Associates with the Interleukin-2 Receptor
Chain and
Inhibits Interleukin-2-dependent Signaling*
M. Javad
Aman
§,
Thi-Sau
Migone
¶,
Atsuo
Sasaki
,
Dana P.
Ascherman,
Ming-hua
Zhu,
Elisabetta
Soldaini,
Kazunori
Imada,
Atsushi
Miyajima**,
Akihiko
Yoshimura
, and
Warren J.
Leonard
From the Laboratory of Molecular Immunology, NHLBI, National
Institutes of Health, Bethesda, Maryland 20892-1674, the ** Institute of
Molecular and Cellular Biosciences, University of Tokyo, Bunkyo-ko
Tokyo 113-0032, Japan, and the
Institute of Life Science, Kurume
University, 2432-3 Aikawa-machi, Kurume 839-0861, Japan
 |
ABSTRACT |
CIS is a cytokine-induced
SH2-containing protein that was originally cloned as an
interleukin (IL)-3-inducible gene. CIS is known to associate with the
IL-3 receptor
chain and erythropoietin receptor and to inhibit
signaling mediated by IL-3 and erythropoietin. We now demonstrate that
CIS also interacts with the IL-2 receptor
chain (IL-2R
). This
interaction requires the A region of IL-2R
(residues 313-382),
which also mediates the association of IL-2R
with Lck and Jak3.
Correspondingly, CIS inhibits functions associated with both of these
kinases: Lck-mediated phosphorylation of IL-2R
and IL-2-mediated
activation of Stat5. Thus, we demonstrate that CIS can negatively
control at least two independent IL-2 signaling pathways. Although a
functional SH2 binding domain of CIS was not required for its
interaction with IL-2R
in vitro, its phosphotyrosine binding capability was essential for the inhibitory action of CIS. On
this basis, we have generated a mutant form of CIS protein with an
altered SH2 domain that acts as a dominant negative and should prove
useful in further understanding CIS action.
 |
INTRODUCTION |
Following antigen encounter, the magnitude and duration of the
subsequent T-cell immune response is critically controlled by the
interaction of IL-21 with
specific high affinity receptors (1, 2). High affinity IL-2 receptors
(IL-2Rs) are composed of three chains, denoted IL-2R
, IL-2R
, and
the common cytokine receptor
chain,
c. IL-2 induces
the heterodimerization of IL-2R
and
c, which together are necessary and sufficient for IL-2 signaling (3, 4). Although
neither IL-2R
nor
c have intrinsic protein-tyrosine kinase catalytic activity, IL-2 rapidly induces tyrosine
phosphorylation of these chains and of intracellular proteins (1, 2).
This is accomplished through activation of receptor-associated tyrosine kinases, which in turn phosphorylate cellular substrates responsible for the transmission of IL-2-induced signals. Two principal
groups of kinases have been reported to associate with the IL-2
receptor subunits: the Src family kinase Lck (1) and the Janus kinases Jak1 and Jak3 (5-7), which activate the transcription factors Stat5a,
Stab5b, and Stat3 (2). Jak1 (5-7) and Lck (1) associate with IL-2R
,
whereas Jak3 associates primarily with
c (5-7) but also
can interact with IL-2R
following stimulation with IL-2 (6, 8). Syk
has also been reported to associate with IL-2R
, although mice
lacking Syk do not have defects related to IL-2 signaling (discussed in
Ref. 2). In addition to these kinases, other signaling molecules can
also associate with the IL-2 receptor. For example, IL-2R
associates
with Shc (9, 10) and phosphatidylinositol 3-kinase (11).
Given the diverse array of molecules associating with cytokine
receptors such as the IL-2 receptor, it is clear that the different signals they exert must be carefully controlled. In general, the functional outcome of biochemical events triggered by cytokines represents a balance between activating and inhibitory signals believed
to function as part of negative feedback loop(s). The inhibitory
signals play an important role in the control of the magnitude and
duration of the cellular response to extracellular stimuli. In the past
few years, several mechanisms for this negative regulation have been
elucidated. These include the activation of phosphatases (12, 13),
SIRPs (14), and a recently discovered family of small SH2-containing
proteins including CIS (cytokine-inducible SH2-containing protein) (15), JAB
(Jak-binding protein) (16, 17), SOCS
(suppressor of cytokine
signaling) (18, 19), and SSI (STAT-induced
STAT inhibitors) (20, 21) proteins (reviewed in
Ref. 22).
CIS (now also denoted as CIS-1) is the prototype member of the
CIS/JAB/SOCS/SSI family of proteins (reviewed in Ref. 22). It is
induced in hematopoietic cells within 30 min of stimulation by IL-2,
IL-3, granulocyte-macrophage colony-stimulating factor, and
erythropoietin, but not by stem cell factor, granulocyte
colony-stimulating factor, or IL-6 (15). STAT response elements have
been identified in the promoter region of CIS, allowing its induction
by a variety of cytokines including IL-2 (23). Once expressed,
CIS/JAB/SOCS/SSI proteins interfere with signaling events and suppress
cytokine-specific cellular responses. JAB/SOCS-1/SSI-1 has been shown
to associate with Jak kinases and to inhibit their catalytic activities.
Previously, it was demonstrated that CIS could associate with the IL-3
receptor
chain and erythropoietin receptor upon appropriate stimulation. Furthermore, CIS was shown to reduce the proliferative responsiveness of cells to IL-3 (15) and to partially inhibit erythropoietin-induced Stat5 phosphorylation and transactivation in
HEK293 cells reconstituted with the erythropoietin receptor and Stat5
(23). We now demonstrate that CIS can associate with IL-2R
and that
it can inhibit more than one IL-2-related signaling pathway.
 |
MATERIALS AND METHODS |
Cells, Transfections, and Reporter Assays--
Peripheral blood
lymphocytes (PBL) were prepared from normal donors using standard
methods. To generate "preactivated PBL," freshly isolated PBL were
cultured for 72 h in RPMI 1640 medium supplemented with 10% fetal
bovine serum, 2 mM glutamine, 100 units/ml each of
penicillin and streptomycin ("complete medium"), and 2 µg/ml
PHA-L (Roche Molecular Biochemicals), and then washed and rested for
24 h in complete medium. NK-like YT cells were cultured and
maintained in complete medium. 32D cells were maintained in complete
medium supplemented with 10
5 M
2-mercaptoethanol and 5% WEHI-3B conditioned medium as a source of
IL-3. Transfectants expressing IL-2R
were generated by
electroporating cells (5 × 106 cells/400 µl) with
linearized pCDNA3zeo (InVitrogen) containing IL-2R
using a Gene
Pulser (Bio-Rad; 300 V, 960 microfarads; average time constant = 30 ms). After 24 h, cells were aliquoted into a 24-well plate and
selected in 0.8 mg/ml ZeocinTM (InVitrogen). Resistant
clones were tested for IL-2R
expression by Western blotting using
goat anti-human IL-2R
antiserum (R & D Systems, Minneapolis, MN).
293T+ cells were cultured in Dulbecco's modified Eagle's
medium (Biofluids) supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 units/ml penicillin, and 100 µg/ml
streptomycin. 293T+ cells at 50% confluency were
transfected using calcium phosphate precipitation reagents (5 Prime
3 Prime, Inc., Boulder, CO), as described previously (24).
Transient transfections of YT and 32D-IL-2R
cells for luciferase
reporter assays were performed using the DEAE-dextran method. Briefly,
1-2 × 106 cells were incubated with up to 10 µg of
plasmid DNA and 200 µg of DEAE-dextran in 1 ml of STBS buffer (25 mM Tris, pH 7.4, 137 mM NaCl, 0.5 mM MgCl2, 0.7 mM CaCl2,
5 mM KCl) at 37 °C for 30 min, followed by washing once
with medium. For YT cells, 18 h after transfection, cells were
stimulated with 2 nM IL-2 for an additional 12-24 h and
then harvested. 32D-IL-2R
cells were incubated with either 0.05%
WEHI-3B conditioned medium (which is sufficient to maintain cell
viability but not growth) or with 2 nM IL-2 or 5% WEHI-3B
conditioned medium for 24-36 h. For luciferase assays, lysates were
prepared using the Luciferase Assay System kit (Promega). Protein
concentrations were measured with a protein assay kit (Bio-Rad), and
5-20 µg of protein were used for luciferase assays according to the
manufacturer's instructions (Promega). Luciferase activity was
measured using a Monolight 2010 luminometer (Analytical Luminescence
Laboratory). Ba/F3 cells were stably transfected with IL-2R
to
create Ba/F3-IL-2R
cells. Ba/F3-IL-2R
-CIS cells additionally
express CIS in pMAMneo (so that its expression can be induced by
steroids; see Ref. 15).
RNA Preparation and Northern Blot
Analyses--
Poly(A)+ RNA was extracted from PBL using
the FastTrack 2.0 Kit (InVitrogen). Northern blotting was performed
using 2 µg/lane of poly(A)+ RNA on 0.8%
formaldehyde-agarose gels as described previously (25), using CIS or
control pHe7 32P-labeled probes. pHe7
(26) is a "housekeeping" gene whose expression is similar before
and after IL-2 stimulation (27).
Constructs and Mutagenesis--
The full-length murine CIS
cDNA was subcloned into the mammalian expression vector pME18S.
FLAG-tagged wild type CIS and truncation mutants of CIS were generated
by polymerase chain reaction, subcloned into pME18S, and sequenced. A
point mutation converting arginine 107 to lysine (R107K) in the SH2
domain was introduced into the CIS cDNA using standard polymerase
chain reaction-based techniques, and the sequence was confirmed by DNA
sequencing. The wild type human IL-2R
and IL-2R
mutant constructs
used in this study have been described (8, 10). Myc-tagged wild type
Lck (Lckwt) and LckY505F were provided by Dr.
J. Ashwell (NCI, National Institutes of Health). The NF-
B-responsive
chloramphenicol acetyltransferase reporter construct, pTK
B3,
containing three copies of the human immunodeficiency virus
B site,
has been described previously (28). The Stat5a, Stat5b, IL-2R
,
c, and Jak3 cDNAs were all human cDNAs. The
-casein reporter construct was generated by cloning three repeats of
the GAS motif from the
-casein promoter and the cytomegalovirus
minimal promoter into pGL-2basic (Promega).
Antibodies, Immunoprecipitations, and Western
Blotting--
Polyclonal rabbit anti-CIS antiserum was prepared as
described previously (15). Anti-Myc mAb 9E10 was from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA); anti-FLAG M2 mAb was from Eastman
Kodak Co.; anti-phosphotyrosine mAbs 4G10 and PY20 were from Upstate Biotechnology, Inc. (Lake Placid, NY) and Transduction Laboratories. Polyclonal rabbit anti-Lck antiserum was a gift of Dr. L. Samelson (NICHD, National Institutes of Health). Mik
1 mAb to IL-2R
was provided by Drs. M. Tsudo (Tokyo Metropolitan Institute) and J. Hakimi
(Hoffmann-La Roche), and Mik
3 mAb to IL-2R
was provided by M. Tsudo. Cells were lysed in Nonidet P-40 lysis buffer (50 mM
Tris-HCl, pH 7.5, 150 mM NaCl, 0.5% Nonidet P-40, 1 mM Na3VO4, 5 mM NaF, 10 µg/ml each leupeptin and aprotonin, and 1 mM
4-(2-aminoethyl)-benzenesulfonyl fluoride hydrochloride) and
centrifuged at 14,000 × g at 4 °C for 15 min.
Lysates were boiled in reducing SDS sample buffer and immunoblotted or
were immunoprecipitated for 1-2 h at 4 °C using specific antibodies
and protein A-Sepharose beads.
 |
RESULTS |
CIS mRNA and Protein Are Potently Induced by IL-2--
To
investigate the potential role of CIS in IL-2 signaling, we first
examined the expression of CIS mRNA in response to IL-2 and
phytohemagglutinin (PHA) in normal human PBL. In unstimulated freshly
isolated PBL, CIS mRNA was not detected (Fig.
1A, lane 1); however, IL-2 induced CIS mRNA within 30 min
(lane 2), and the levels of CIS mRNA
increased with time, with high level expression being sustained for at
least 24 h (lanes 4, 6, and
8). Stimulation of PBL with PHA also induced CIS, but with a
slower time course so that it was 4 h before even very low levels
of CIS mRNA were detected (compare lanes 3,
5, and 7 with lane 1).
However, by 24 h, the level of CIS expression was comparable with
that seen with IL-2 (lane 9). These data suggest
that PHA may not induce CIS expression directly but rather indirectly
through induction of IL-2 production, given that at least 4 h is
typically needed before appreciable levels of IL-2 protein can be
detected after PHA activation. When PBL were preactivated with PHA for
3 days and then rested overnight in IL-2-free medium, a treatment that induces maximal expression of high affinity IL-2 receptors and primes
cells for potent cellular responsiveness to IL-2, CIS mRNA expression was rapidly induced by IL-2 and sustained at a high level
for at least 24 h (Fig. 1B, lanes
1-4). We also investigated the expression pattern of CIS
protein in these cells. CIS protein was potently expressed within
24 h, and high levels were maintained for at least 72 h (Fig.
1C, lanes 1-4).

View larger version (51K):
[in this window]
[in a new window]
|
Fig. 1.
Induction of CIS mRNA and protein
expression by IL-2 and association of CIS with
IL-2R . A, fresh PBL were
stimulated with either 2 nM IL-2 (lanes 1, 3, 5, and 7) or 2 µg/ml PHA (lanes 2, 4, 6,
and 8) for the indicated times. Poly(A)+ RNA was
extracted and analyzed by Northern blotting using a
32P-labeled murine CIS as a probe (upper panel). The blot was stripped and reprobed using
pHe7 (lower panel) to control for
variations in loading. In addition to the major CIS transcript, a minor
species of approximately 4.3 kilobases was detected. The basis for this
form is unclear, but it may result from utilization of an alternative
polyadenylation signal. B, preactivated PBL were
unstimulated (lane 1) or stimulated with IL-2 for
1, 4, or 24 h (lanes 2-4). The blot was
then hybridized with CIS and pHe7 as in A.
C, preactivated PBL were stimulated with 2 nM
IL-2, and CIS protein expression was analyzed by Western blotting.
D, lysates were immunoprecipitated with an anti-IL-2R
antibody, Mik 3, and then Western blotted with anti-CIS
antibody.
|
|
CIS Physically Associates with the "A" Region (Amino Acids
313-382) of IL-2R
in a Fashion That Does Not Require a Classical
SH2-Phosphotyrosine-mediated Interaction--
As noted above, CIS is
induced by both erythropoietin and IL-3 and can associate with both the
erythropoietin receptor and the murine IL-3 receptor
chain (15). We
therefore tested the ability of CIS to associate with the IL-2R
chain. Lysates from IL-2-stimulated, preactivated PBL were
immunoprecipitated with Mik
3 mAb to IL-2R
and then Western
blotted with anti-CIS antibodies. As shown in Fig. 1D, CIS
coprecipitated with IL-2R
, indicating a physical interaction between
these two proteins. Although the degree of apparent interaction was
inducible (Fig. 1D), it was not as marked as was the
inducibility of CIS (Fig. 1C). To further investigate this
situation, we also evaluated coprecipitation in Ba/F3 cells stably
transfected with IL-2R
(Fig. 2). In
these cells, IL-2 stimulates CIS expression (Fig. 2A).
However, as in PBL, it was difficult to detect a CIS-IL-2R
interaction with anti-IL-2R
antibodies (data not shown), but this
interaction was revealed with more sensitive anti-phosphotyrosine
antibodies (Fig. 2B). The relatively weak coprecipitation of
CIS and IL-2R
could reflect low stoichiometry; alternatively, a
higher stoichiometry might exist but might not be readily detected
given that neither the anti-CIS nor anti-IL-2R
antibodies are
particularly robust. It is also possible that the weak coprecipitation
could also reflect a comparatively low affinity or transient
interactions.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 2.
Association of CIS with
IL-2R in Ba/F3-IL-2R cells. A, induction of CIS protein by IL-2 in
Ba/F3 cells. Cells were cultured for 0, 0.5, 1, or 2 h in IL-2,
and then total cell lysates were Western blotted with anti-CIS
antisera. B, cells were not stimulated or stimulated with
IL-2 for 1 h. Lysates were then immunoprecipitated with anti-CIS
or anti-IL-2R antibodies and Western blotted with
anti-phosphotyrosine. The position of IL-2R was determined by
alignment with an anti-IL-2R immunoprecipitation.
|
|
To map the region of IL-2R
required for its interaction with CIS, we
performed coimmunoprecipitation experiments in 293 T+ cells
transfected with murine CIS plus wild type IL-2R
or IL-2R
mutants
containing various internal deletions or C-terminal truncations (see
Fig. 3A for a schematic of
IL-2R
, including the locations of the A (residues 313-382) and S
(residues 267-323). For unclear reasons, we consistently observed
lower CIS expression when CIS was co-expressed with mutants of IL-2R
lacking either the A or S regions. Therefore, we increased the amount
of the CIS plasmid cotransfected with IL-2R
A or IL-2R
S in
order to achieve more similar levels of CIS expression (Fig.
3B, lanes 4 and 5 versus lane 1; middle
panel; note that murine CIS is routinely detected as a
doublet). When CIS and wild type IL-2R
were cotransfected (lane 1) and then immunoprecipitated with Mik
1
mAb to IL-2R
, CIS was efficiently coprecipitated (lane
1, top panel). Deletion of the S
region partially decreased the degree of association of IL-2R
with
CIS (lanes 3 and 5), whereas deletion
of the A region of IL-2R
abrogated CIS interaction (lanes
2 and 4; note that no CIS was coprecipitated in
lane 4 (upper panel) although expression of CIS
in this lane was higher than in lane 3 (middle panel), where CIS weakly coprecipitated
with IL-2R
S).

View larger version (47K):
[in this window]
[in a new window]
|
Fig. 3.
CIS association with IL-2R requires the A region (amino acids 313-382) of
IL-2R . A, schematic of
IL-2R , showing the S region, A region, and locations of tyrosines.
293T+ cells were co-transfected with CIS and either wild
type IL-2R or the IL-2R internal deletion mutants
IL-2R A and IL-2R S (B) or
the indicated C-terminal truncation mutants of IL-2R (C).
Lysates were immunoprecipitated with Mik 1 anti-IL-2R mAb and then
Western blotted with anti-CIS (upper panels) or a
polyclonal antiserum to IL-2R (lower panels).
Lysates were also Western blotted with anti-CIS to confirm the
expression of CIS in different transfectants (middle panels).
|
|
We next analyzed several C-terminal IL-2R
truncation mutants for
their abilities to bind CIS. These experiments revealed that the
sequences beyond amino acid 350 were dispensable for this interaction,
while truncation at amino acid 330 abrogated the association (Fig.
3C, upper panel). Therefore, these
results identify amino acids 330-350 as critical for CIS binding,
complementing the deletion analysis. The fact that a mutant lacking the
S region (residues 267-323) showed reduced association with CIS (Fig.
3B) suggests the presence of an additional direct or
indirect contact point within the S region or suggests that deletion of
the S region has conformational effects resulting in reduced association.
To clarify the region of CIS that mediates its interaction with
IL-2R
, we generated wild type CIS and C-terminal truncation mutants
of CIS that were FLAG-tagged at their C termini. The truncation mutants
contained either the first 82 amino acids (the residues N-terminal to
the SH2 domain, denoted CISNT) or the first 177 amino acids
(retaining the N-terminal region as well as the SH2 domain, denoted
CIS
CT)(Fig.
4A). Following coexpression of
these constructs with wild type IL-2R
in 293 T+ cells,
immunoprecipitation experiments were performed (Fig. 4B, top panel, lanes 1-3).
Whereas CIS
CT could associate with IL-2R
as well as
wild type CIS (Fig. 4B, middle panel,
lane 1 versus lane
3), CISNT (which lacks the SH2 domain) could not
(lane 2), suggesting that the interaction of CIS
with IL-2R
might involve a classical SH2/phosphotyrosine interaction. This hypothesis is consistent with the suggestion that
tyrosine-phosphorylated forms of IL-3R
and the erythropoietin receptor could associate with CIS (15). Surprisingly, however, the
association of CIS with IL-2R
did not appear to require the tyrosine
phosphorylation of IL-2R
as demonstrated by the ability of CIS to
associate with an IL-2R
mutant in which all six cytoplasmic tyrosines were mutated to phenylalanines (IL-2R
FFFFFF)
(Fig. 4C, middle panel,
lane 3 versus lane
1). Even wild type IL-2R
does not appear to be
phosphorylated in these 293 transfections (data not shown and shown
below in Fig. 6B, top panel,
lane 1). However, we used the
IL-2R
FFFFFF construct to exclude the possibility that a
low but undetectable level of tyrosine phosphorylation of IL-2R
played a role in the interaction seen in Fig. 4C. To more
directly assess the role of the CIS SH2 domain in the CIS-IL-2R
interaction, we prepared a CIS mutant in which arginine 107 in the
phosphotyrosine binding FLVR motif was changed to lysine
(CISR107K). While this type of mutation is known to disrupt
the ability of SH2 domains to bind phosphotyrosine (29-31), it had
little effect on the ability of CIS to associate with IL-2R
(Fig.
4C, middle panel, lane
2). Together, the above results indicate that at least in vitro the CIS-IL-2R
interaction does not require a
classical SH2-phosphotyrosine interaction between CIS and IL-2R
.
Therefore, the ability of IL-2R
to interact with
CIS
CT but not CISNT suggests either that
other residues distinct from the FLVR motif in the SH2 region are
important for binding or that the CISNT construct has a
severely altered structure resulting from deletion of the SH2 domain.
The above results do not exclude a partial contribution of an
SH2-mediated interaction of CIS with IL-2R
; they instead demonstrate
that non-SH2-mediated interactions also exist. Interestingly, in 293 cells, the common
chain (
c) of the IL-3, IL-5, and
granulocyte-macrophage colony-stimulating factor receptors associated
with CIS and augmenting its phosphorylation by cotransfecting Jak1 did
not significantly increase its association with CIS (Fig.
5). Previously, CIS was shown to
associate with IL-3R
and the EPO receptor after ligand stimulation
(15). However, the role of ligand requirement for this induction may
have been in part related to the stronger induction of CIS in the
presence of ligand. Thus, like IL-2R
,
c may at least
in part associate with CIS independently of a phosphotyrosine-SH2
interaction.

View larger version (40K):
[in this window]
[in a new window]
|
Fig. 4.
The CIS-IL-2R association is not mediated by a classical
SH2-phosphotyrosine-mediated interaction. A, schematic
of CIS, showing the location of the SH2 domain and the regions
comprising the CIS CT and CISNT constructs.
B, 293T+ cells were transfected with wild type
IL-2R along with FLAG-tagged forms of wild type CIS (lane 3) or the indicated truncation mutants of CIS
(lanes 1 and 2). Expression of each
construct was confirmed by Western blotting with anti-FLAG antibodies
(M2, top panel). Lysates were
immunoprecipitated with Mik 1 antibody and then Western blotted with
anti-FLAG (middle panel) or polyclonal antiserum
to IL-2R (lower panel). C,
293T+ cells were transfected with the indicated constructs,
and the IL-2R /CIS association was analyzed as described in
B.
|
|

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 5.
Association of c and CIS is not substantially affected
by Jak1-mediated tyrosine phosphorylation of c in 293T+ cells. 293T+ cells were transfected with CIS
plus either IL-2R , c, or c plus Jak1.
Lysates were then immunoprecipitated with antibodies to IL-2R or
c followed by Western blotting with antibodies to
phosphotyrosine, c, IL-2R , or CIS.
|
|
CIS Inhibits Lck-mediated, but Not Jak1-mediated, Tyrosine
Phosphorylation of IL-2R
--
Because CIS serves as a negative
regulator of IL-3-mediated signaling, we investigated the ability of
CIS to inhibit IL-2 signaling. Since the region of IL-2R
(the A
region) that binds CIS is also known to mediate the interaction of
IL-2R
with Lck (1) and Jak3 (8), we focused on IL-2 signaling
effects associated with these kinases. Although the functional effects
of Lck for IL-2 signaling remain unclear, it can associate with and
phosphorylate IL-2R
(1). We therefore examined the effect of CIS on
the tyrosine phosphorylation of IL-2R
mediated by Lck; as a control, we also examined the effect of CIS on the phosphorylation of IL-2R
by Jak1, a kinase known to phosphorylate IL-2R
but which associates primarily with the S region (reviewed in Refs. 1 and 2) (see Fig.
6A, lanes
9 and 10 versus lanes
1 and 2). Interestingly, co-expression
experiments in 293T+ cells revealed that CIS did not
inhibit Jak1-mediated phosphorylation of IL-2R
(Fig. 6A,
lane 10 versus lane
9), but it reproducibly could partially inhibit the ability
of a constitutively active form of Lck (LckY505F) to
mediate phosphorylation of IL-2R
(Fig. 6A,
lane 8 versus lane
7, upper panel; Fig. 6B,
lane 3 versus lane
2, upper panel). This effect was
specific, since CIS did not significantly affect Lck
autophosphorylation (Fig. 6A, lane 8 versus lane 7 and lane 4 versus lane 3,
middle panel) or phosphorylation of an exogenous peptide substrate, NH2-KVEKIGEGTYGVVKK-COOH, known to be
efficiently phosphorylated by Src family kinases (Upstate Biotechnology
Src family kinase assay kit; data not shown). When wild type Lck was used in place of LckY505F, phosphorylation of IL-2R
was
more difficult to detect (lanes 5 and
6); however, phosphorylation seen after longer exposures was
also inhibited by CIS (data not shown). We considered the possibility
that CIS might inhibit the binding of Lck to IL-2R
, since both
proteins bind to the A region (1); however, when Lck and IL-2R
were
expressed with CIS in 293T+ cells, Lck binding to IL-2R
was either not affected or only slightly diminished (Fig.
6C, panel 1, lane
2 versus lane 1, and data
not shown), suggesting that competition for binding cannot explain this
inhibitory effect of CIS.

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 6.
CIS inhibits Lck-mediated phosphorylation of
IL-2R . A, 293T+ cells
were transfected with the indicated plasmids (wild type or
constitutively activated forms of Lck, both tagged with Myc epitopes,
IL-2R , Jak1, and/or wild type CIS or CISR107K), and
lysed. Lysates were immunoprecipitated using Mik 1 or 9E10 (anti-Myc)
mAbs. Samples were run on gels and Western blotted with the indicated
antibodies (4G10 or anti-IL-2R ). Note that analogous to the lack of
effect of CIS on Jak1 phosphorylation of IL-2R , there is no effect
of CIS on Jak1 autophosphorylation (lanes 9 and
10, upper panel). B and
C, IL-2R and LckY505F were cotransfected with CIS or
LckY505F. Lysates were either directly blotted as indicated
(lower panels) or were first immunoprecipitated
with anti-IL-2R and then blotted as indicated (upper panels).
|
|
CIS Inhibits IL-2-mediated Activation of Stat5--
Like Lck, Jak3
also associates with the A region of IL-2R
(8). Given the importance
of Jak3 for Stat5 activation (32), we investigated whether CIS
inhibited IL-2-mediated activation of Stat5 (which is important for the
transcription of a number of IL-2-responsive genes, such as CIS (23),
oncostatin M (33), and the IL-2 receptor
chain (34-37)). We first
evaluated whether CIS could inhibit IL-2-induced tyrosine
phosphorylation of Stat5 using an in vitro reconstitution
system similar to that previously described (8, 32). 293T+
cells were transfected with cDNAs encoding wild type or mutant forms of human IL-2R
,
c, Jak3, Stat5a, and Stat5b,
with or without wild type CIS or CISR107K. When cells were
transfected with the vector control (pME18S), as expected, we observed
potent IL-2-induced phosphorylation of Stat5 (Fig.
7A, lane
2 versus lane 1). This
activity was markedly reduced in the presence of wild type CIS (Fig.
7A, lane 4 versus lane 2); in contrast, the CISR107K
mutant had no significant inhibitory effect (lanes
5 and 6). These data suggested a critical
functional role for the phosphotyrosine binding activity of the SH2
domain of CIS in the inhibition of IL-2-induced Stat5 tyrosine
phosphorylation, in contrast to its dispensability for receptor binding
in vitro. When IL-2R
A, which did not associate with
CIS (Fig. 3B), was used in place of wild type IL-2R
, CIS
had much less of an inhibitory effect on Stat5 phosphorylation
(lanes 9 and 10 versus
lanes 7 and 8). Coupled with the
receptor binding data, these results demonstrate that at least two
functional regions of CIS are involved in the negative regulation of
IL-2 signaling, one for receptor binding and one for binding
phosphotyrosines. The ability of CIS to inhibit Stat5 tyrosine
phosphorylation was confirmed in Ba/F3-IL-2R
-CIS cells, in which CIS
expression is under control of a glucocorticoid-responsive promoter. As
shown in Fig. 7C, treatment with dexamethasone induced CIS
expression (third panel, lanes
4-6) and correspondingly diminished the tyrosine
phosphorylation of Stat5 by IL-2 (Fig. 7C, top
panel). However, such treatment did not affect tyrosine
phosphorylation of stress-activated protein kinase (SAPK)
(both panels).

View larger version (49K):
[in this window]
[in a new window]
|
Fig. 7.
CIS inhibits phosphorylation of Stat5.
A and B, 293T+ cells were transfected
with c, Stat5a, Stat5b, Jak3, and either
IL-2R wt or IL-2R A along with pME18S,
CISwt, or CISR107K. After 16 h, cells from
each transfection were plated in duplicate. 24 h later, one set of
cells was stimulated with 2 nM IL-2 for 15 min. Cells were
then harvested, and cytoplasmic and nuclear extracts were prepared.
Stat5 was immunoprecipitated from lysates using a mixture of polyclonal
antibodies to Stat5a and Stat5b and subjected to Western blotting with
4G10 (A) or anti-Stat5 (B). In A, note
that IL-2-induced Stat5 tyrosine phosphorylation is seen even in the
absence of the A region in this overexpression system, presumably
because Jak3 is recruited via c. C,
Ba/F3-IL-2R -CIS cells were treated with Me2SO
(DMSO) or dexamethasone (to induce CIS) and stimulated with
IL-2 for 0, 5, or 10 min. Lysates were then immunoprecipitated and
Western blotted with the indicated antibodies. As a control, it is
shown that CIS expression did not affect phosphorylation of
stress-activated protein kinase (SAPK).
|
|
Given the inhibition of IL-2-mediated tyrosine phosphorylation of
Stat5, we next investigated the effect of CIS on
Stat5-dependent transcription using a
-casein luciferase
reporter construct. As shown in Fig.
8A, both IL-3 and IL-2 could
induce the activity of this reporter construct in 32D-IL-2R
cells
(32D cells stably transfected with IL-2R
). Although the effect of
IL-3 was consistently greater than that of IL-2 in these cells, CIS
similarly inhibited the effects of both of these cytokines.
Interestingly, transfection of cells with CISR107K markedly
enhanced Stat5 transcriptional activity (Fig. 8B),
indicating that it could act as a dominant negative CIS mutant by
competing with endogenous CIS protein present in 32D cells. Note that
because CIS is a negative regulator, its "dominant negative" mutant
actually enhances activity.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 8.
IL-2-induced Stat5-dependent
transcription is repressed by CISwt and enhanced by
CISR107K. 32D-IL-2R cells were transfected with the
-casein-luciferase reporter construct and either empty pME18S vector
or wild type or mutant CIS. Transfectants were cultured with medium
alone, with WEHI conditioned medium (for 32D-IL-2R cells), or with
IL-2, as indicated. Luciferase activity was measured 48 h after
transfection.
|
|
To exclude the formal possibility that CIS was nonspecifically
inhibiting transcription, we examined the effect of CIS on NF-
B-dependent transcription in YT cells using a
construct containing three repeats of the human immunodeficiency
virus-NF-
B binding element upstream of the TK promoter in a
chloramphenicol acetyltransferase reporter construct (pTK
B; Ref.
28). As shown in Fig. 9, PMA plus
ionomycin induced NF-
B activity, and this induction was not
inhibited by CIS. Similar results (data not shown) were obtained with a
reporter construct containing IL-2 receptor
chain promoter PRRI
element (38) that consists of an NF-
B and an SRE site (39). These
data show that the reduced transcriptional activity of the
Stat5-reporter construct was due to specific targeting of this
IL-2-mediated signaling pathway by CIS rather than a nonspecific toxic
effect.

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 9.
NF- B activity is not
inhibited by CIS. YT cells were transfected with the
pTK B3HIVCAT reporter construct along with either empty pME18S vector
or CIS. Transfectants were cultured with or without PMA plus ionomycin,
and chloramphenicol acetyltransferase activity was analyzed by thin
layer chromatography after 48 h.
|
|
 |
DISCUSSION |
Cytokines comprise a large number of diverse molecules that induce
a broad range of signals. Signaling by interferons and by cytokines
whose receptors are members of the cytokine receptor superfamily, also
known as type I cytokine receptors, involve the activation of Jak
kinases and STAT proteins (40, 41). To counteract these positive
regulatory signals, a number of potential negative regulatory
mechanisms exist, including protein degradation, phosphatase
activation, and induction of the CIS/JAB/SOCS/SSI proteins (reviewed in
Refs. 12 and 22).
Although the available data are still limited, most CIS/JAB/SOCS/SSI
family proteins that have been studied exert negative regulatory
activities (16, 18, 20, 22). However, comparatively little is known
about the mechanisms by which these proteins can act. The presence of
an SH2 domain in CIS/JAB/SOCS/SSI family proteins suggests that
phosphotyrosine binding is likely to be important for the actions of
these proteins, and in this regard, it was previously reported that
tyrosine-phosphorylated forms of IL-3R
and the erythropoietin
receptors associate with CIS (15). In the current study, we found that
CIS could associate with IL-2R
; analysis of internal deletion and
C-terminal truncation mutants suggested that the amino acid 330-350
region of IL-2R
is important for its interaction with CIS.
Surprisingly, although this region contains a tyrosine, substantial
CIS-IL-2R
association occurred in vitro even following
mutation of the critical arginine (Arg107) in the FLVR
sequence of the SH2 domain of CIS or when all of the tyrosines in the
IL-2R
cytoplasmic domain were mutated. These data therefore indicate
that the interaction of CIS and IL-2R
in vitro does not
require tyrosine phosphorylation. Although it is formally possible that
at physiological levels of CIS, tyrosine phosphorylation of IL-2R
might enhance the interaction, the sequence surrounding
Tyr338 (NQGYFFFH) is more typical of a motif for binding
PTB phosphotyrosine binding domains than SH2 domains. Consistent with
this notion, it has been demonstrated that the phosphorylated
Tyr338 motif binds to Shc via the Shc PTB domain rather
than through the Shc SH2 domain (42). Nevertheless, the fact that IL-2
induces both CIS expression and tyrosine phosphorylation of IL-2R
suggests that much of the physiologically induced interaction will be
between CIS and phosphorylated IL-2R
.
In addition to defining the IL-2R
-CIS interaction and clarifying the
time course of CIS induction in normal human PBL, we have demonstrated
that CIS can inhibit two signaling pathways: 1) Lck-mediated (but not
Jak1-mediated) phosphorylation of IL-2R
and 2)
Stat5-dependent transcription. Given that CIS is itself regulated by Stat5 (23), the latter result indicates that CIS negatively regulates its own production as well as that of other Stat5-dependent proteins. Although the SH2 domain of CIS
was not required for its interaction with IL-2R
, it was essential
for the ability of CIS to act as a negative regulator. This was
demonstrated by the ability of the CISR107K mutant
(containing a mutation in the FLVR sequence of the SH2 domain) to
function as a dominant negative, enhancing Stat5-dependent transcription in 32D-IL-2R
cells, presumably by reversing the inhibitory effect of the endogenous CIS produced by these cells. The
fact that CISR107K did not increase tyrosine
phosphorylation of Stat5 in 293 T+ cells can be explained
by the lack of endogenous CIS in these cells (i.e. the
"dominant" negative effect was, as expected, only seen in a setting
where endogenous wild type CIS was present). To our knowledge, our data
provide the first direct evidence for the functional importance of the
CIS SH2 domain.
Our study raises a number of general questions. First, given the large
number of CIS/JAB/SOCS/SSI family proteins, how many of these other
proteins will potentially contribute to IL-2-dependent signaling? Second, within other settings, how many of these proteins will exert effects related to inhibition of Src family kinases and/or
STAT proteins? Finally, what is the mechanism of action of CIS?
Although the mechanism is not fully understood, we demonstrate that the
negative regulatory effects of CIS are dependent on both receptor
binding and on the integrity of the SH2 domain. Furthermore, we
demonstrate that an SH2 mutant of CIS can act as a dominant negative.
Because the phosphotyrosine binding ability of the SH2 domain is not
required for CIS binding to IL-2R
, our data suggest that the CIS SH2
domain may bind other critical phosphoproteins with which CIS must
interact in order to exert its inhibitory function on STAT protein
activation. CIS may therefore be a novel type of adaptor protein that
contains a single SH2 domain and lacks SH3 domains. The SH2 domain of
CIS therefore may prove to be a valuable probe for identifying
interacting proteins that help mediate CIS's negative regulatory effect.
 |
ACKNOWLEDGEMENTS |
We thank L. E. Samelson for antisera to
Lck, J. Ashwell for wild type Lck and LckF505 expression
vectors, J. Yodoi for YT cells, and J.-X. Lin for preparing the
-casein reporter construct. We thank J.-X. Lin and S. John for
valuable discussions and critical comments.
 |
Note Added in Proof |
Since submission, of this manuscript,
Matsumoto et al. (Matsumoto, A., Seki, Y., Kubo, M.,
Ohtsuka, S., Suzuki, A., Hayashi, I., Tsuji, K., Nakahata, T., Okabe,
M., Yamada, S., and Yoshimura, A. (1999) Mol. Cell Biol.
9, 6396-6407) reported suppression of IL-2-induced Il-2R
up-regulation as well as proliferation of T cells from CIS transgenic
mice. These findings are consistent with our report on the negative
regulation of IL-2 signaling by CIS.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
These authors contributed equally to this study.
§
Present address: Beirne Carter Center for Immunology Research,
Bldg. MR4, Room 4022, HSC, University of Virginia, Charlottesville, VA 22908.
¶
Present address: DNAX Research Institute, 901 California Ave.,
Palo Alto, CA 94304.

To whom correspondence should be addressed: Bldg. 10, Rm.
7N252, NHLBI, National Institutes of Health, Bethesda, MD 20892.
 |
ABBREVIATIONS |
The abbreviations used are:
IL, interleukin;
IL-2R, interleukin-2 receptor;
PBL, peripheral blood lymphocytes;
mAb, monoclonal antibody;
PHA, phytohemagglutinin;
SH2, Src homology 2;
STAT, signal transducers and activators of transcription.
 |
REFERENCES |
| 1.
|
Taniguchi, T.
(1995)
Science
268,
251-255[Abstract/Free Full Text]
|
| 2.
|
Lin, J.-X.,
and Leonard, W. J.
(1997)
Cytokine Growth Factor Rev.
8,
313-332[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Nakamura, Y.,
Russell, S. M.,
Mess, S. A.,
Friedmann, M.,
Erdos, M.,
Francois, C.,
Jacques, Y.,
Adelstein, S.,
and Leonard, W. J.
(1994)
Nature
369,
330-333[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Nelson, B. H.,
Lord, J. D.,
and Greenberg, P. D.
(1994)
Nature
369,
333-336[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Boussiotis, V. A.,
Barber, D. L.,
Nakarai, T.,
Freeman, G. J.,
Gribben, J. G.,
Bernstein, G. M.,
D'Andrea, A. D.,
Ritz, J.,
and Nadler, L. M.
(1994)
Science
266,
1039-1042[Abstract/Free Full Text]
|
| 6.
|
Russell, S. M.,
Johnston, J. A.,
Noguchi, M.,
Kawamura, M.,
Bacon, C. M.,
Friedmann, M.,
Berg, M.,
McVicar, D. W.,
Witthuhn, B. A.,
Silvennoinen, O.,
Goldman, A. S.,
Schmalstieg, G. C.,
Ihle, J. N.,
O'Shea, J. J.,
and Leonard, W. J.
(1994)
Science
266,
1042-1045[Abstract/Free Full Text]
|
| 7.
|
Miyazaki, T.,
Kawahara, A.,
Fujii, H.,
Nakagawa, Y.,
Minami, Y.,
Liu, Z. J.,
Oishi, I.,
Silvennoinen, O.,
Witthuhn, B. A.,
Ihle, J. N.,
and Taniguchi, T.
(1994)
Science
266,
1045-1047[Abstract/Free Full Text]
|
| 8.
|
Zhu, M.,
Berry, J. A.,
Russell, S. M.,
and Leonard, W. J.
(1998)
J. Biol. Chem.
273,
10719-10725[Abstract/Free Full Text]
|
| 9.
|
Ravichandran, K. S.,
and Burakoff, S.
(1994)
J. Biol. Chem.
269,
1599-1602[Abstract/Free Full Text]
|
| 10.
|
Friedmann, M. C.,
Migone, T.-S.,
Russell, S. M.,
and Leonard, W. J.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
2077-2082[Abstract/Free Full Text]
|
| 11.
|
Remillard, B.,
Petrillo, R.,
Maslinsi, W.,
Tsudo, M.,
Strom, T. B.,
Cantley, L.,
and Varticovski, L.
(1991)
J. Biol. Chem.
266,
14167-14170[Abstract/Free Full Text]
|
| 12.
|
Neel, B. G.
(1997)
Curr. Opin. Immunol.
9,
405-420[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Damen, J. E.,
Liu, L.,
Rosten, P.,
Humphries, R. K.,
Jefferson, A. B.,
Majerus, P. W.,
and Krystal, G.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
1689-1693[Abstract/Free Full Text]
|
| 14.
|
Kharitonenkov, A.,
Chen, Z.,
Sures, I.,
Wang, H.,
Schilling, J.,
and Ullrich, A.
(1997)
Nature
386,
181-186[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Yoshimura, A.,
Ohkubo, T.,
Kiguchi, T.,
Jenkins, N. A.,
Gilbert, D. J.,
Copeland, N. G.,
Hara, T.,
and Miyajima, A.
(1995)
EMBO J.
14,
2816-2826[Medline]
[Order article via Infotrieve]
|
| 16.
|
Endo, T. A.,
Masuhara, M.,
Yokouchi, M.,
Suzuki, R.,
Sakamoto, H.,
Mitsui, K.,
Matsumoto, A.,
Tanimura, S.,
Ohtsubo, M.,
Misawa, H.,
Miyazaki, T.,
Leonor, N.,
Taniguchi, T.,
Fujita, T.,
Kanakura, Y.,
Komiya, S.,
and Yoshimura, A.
(1997)
Nature
387,
921-924[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Masuhara, M.,
Sakamoto, H.,
Matsumoto, A.,
Suzuki, R.,
Yasukawa, H.,
Mitsui, K.,
Wakioka, T.,
Tanimura, S.,
Sasaki, A.,
Misawa, H.,
Yokouchi, M.,
Ohtsubo, M.,
and Yoshimura, A.
(1997)
Biochem. Biophys. Res. Commun.
239,
439-446[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Starr, R.,
Willson, T. A.,
Viney, E. M.,
Murray, L. J. L.,
Rayner, J. R.,
Jenkin, B. J.,
Gonda, T. J.,
Alexander, W. S.,
Metcalf, D.,
Nicola, N. A.,
and Hilton, D. J.
(1997)
Nature
387,
917-921[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Hilton, D. J.,
Richardson, R. T.,
Alexander, W. S.,
Viney, E. M.,
Willson, T. A.,
Sprigg, N. S.,
Starr, R.,
Nicholson, S. E.,
Metcalf, D.,
and Nicola, N. A.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
114-119[Abstract/Free Full Text]
|
| 20.
|
Naka, T.,
Narazaki, M.,
Hirata, M.,
Matsumoto, T.,
Minamoto, S.,
Aono, A.,
Nishimoto, N.,
Kajita, T.,
Taga, T.,
Yoshizaki, K.,
Akira, S.,
and Kishimoto, T.
(1997)
Nature
387,
924-929[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Minamoto, S.,
Ikegame, K.,
Ueno, K.,
Narazaki, M.,
Naka, T.,
Yamamoto, H.,
Matsumoto, T.,
Saito, H.,
Hosoe, S.,
and Kishimoto, T.
(1997)
Biochem. Biophys. Res. Commun.
237,
79-83[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Aman, M. J.,
and Leonard, W. J.
(1997)
Curr. Biol.
12,
R784-R788
|
| 23.
|
Matsumoto, A.,
Masuhara, M.,
Mitsui, K.,
Yokouchi, M.,
Ohtsubo, M.,
Misawa, H.,
Miyajima, A.,
and Yoshimura, A.
(1997)
Blood
89,
3148-3154[Abstract/Free Full Text]
|
| 24.
|
Aman, M. J.,
Tayebi, N.,
Obiri, N. I.,
Puri, R. K.,
Modi, W. S.,
and Leonard, W. J.
(1996)
J. Biol. Chem.
271,
29265-29270[Abstract/Free Full Text]
|
| 25.
|
Ascherman, D. P.,
Migone, T.-S.,
Friedmann, M. C.,
and Leonard, W. J.
(1997)
J. Biol. Chem.
272,
8704-8709[Abstract/Free Full Text]
|
| 26.
|
Kaczmarek, L.,
Calabretta, B.,
Kao, H.-T.,
Heinz, N.,
Nevins, J.,
and Baserga, R.
(1987)
J. Cell Biol.
104,
183-187[Abstract/Free Full Text]
|
| 27.
|
Otani, H.,
Erdos, M.,
and Leonard, W. J.
(1993)
J. Biol. Chem.
268,
22733-22736[Abstract/Free Full Text]
|
| 28.
|
Lin, J.-X.,
Bhat, N.,
John, S.,
Queale, W. S.,
and Leonard, W. J.
(1993)
Mol. Cell. Biol.
13,
6201-6210[Abstract/Free Full Text]
|
| 29.
|
Mayer, B. J.,
Jackson, P. K.,
Van Etten, R. A.,
and Baltimore, D.
(1992)
Mol. Cell. Biol.
12,
609-618[Abstract/Free Full Text]
|
| 30.
|
Waksman, G.,
Kominos, D.,
Robertson, S. C.,
Pant, N.,
Baltimore, D.,
Birge, R. B.,
Cowburn, D.,
Hanafusa, H.,
Mayer, B. J.,
Overduin, M.,
Resh, M. D.,
Rios, C. B.,
Silverman, L.,
and Kuriyan, J.
(1992)
Nature
358,
646-653[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Eck, M. J.,
Shoelson, S. E.,
and Harrison, S. C.
(1993)
Nature
362,
87-91[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Lin, J.-X.,
Mietz, J.,
Modi, W. S.,
John, S.,
and Leonard, W. J.
(1996)
J. Biol. Chem.
271,
10738-10744[Abstract/Free Full Text]
|
| 33.
|
Yoshimura, A.,
Ichihara, M.,
Kinjyo, I.,
Moriyama, M.,
Copeland, N. G.,
Gilbert, D. J.,
Jenkins, N. A.,
Hara, T.,
and Miyajima, A.
(1996)
EMBO J.
15,
1055-1063[Medline]
[Order article via Infotrieve]
|
| 34.
|
John, S.,
Robbins, C. M.,
and Leonard, W. J.
(1996)
EMBO J.
15,
5627-5635[Medline]
[Order article via Infotrieve]
|
| 35.
|
Sperisen, P.,
Wang, S. M.,
Soldaini, E.,
Pla, M.,
Rusterholz, C.,
Bucher, P.,
Corthesy, P.,
Reichenbach, P.,
and Nabholz, M.
(1995)
J. Biol. Chem.
270,
10743-10753[Abstract/Free Full Text]
|
| 36.
|
Lécine, P.,
Algarté, M.,
Rameil, P.,
Beadling, C.,
Bucher, P.,
Nabholz, M.,
and Imbert, J.
(1996)
Mol. Cell. Biol.
16,
6829-6840[Abstract]
|
| 37.
|
Nakajima, H.,
Liu, X.-W.,
Wynshaw-Boris, A.,
Rosenthal, L. A.,
Imada, K.,
Feldman, G.,
Finbloom, D. S.,
Hennighausen, L.,
and Leonard, W. J.
(1997)
Immunity
7,
691-701[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
John, S.,
Reeves, R. B.,
Lin, J.-X.,
Child, R.,
Leiden, J. M.,
Thompson, C. B.,
and Leonard, W. J.
(1995)
Mol. Cell. Biol.
10,
1786-1796
|
| 39.
|
Toledano, M. B.,
Roman, D. G.,
Halden, N. F.,
Lin, B. B.,
and Leonard, W. J.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
1830-1834[Abstract/Free Full Text]
|
| 40.
|
Darnell, J. E., Jr.
(1997)
Science
277,
1630-1636[Abstract/Free Full Text]
|
| 41.
|
Leonard, W. J.,
and O'Shea, J. J.
(1998)
Annu. Rev. Immunol.
16,
293-322[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Ravichandran, K. S.,
Igras, V.,
Shoelson, S. E.,
Fesik, S. W.,
and Burakoff, S. J.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
5275-5280[Abstract/Free Full Text]
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg